Question from Deputy Charles Ward - PQ 15673-26
Deputy Ward asked about the number of additional staff that needed in each community hospital in Donegal. Read the HSE response.
- Published date:
- :
Corporate publications
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Showing 1371 to 1380 of 5499 results
Question from Deputy Ken O'Flynn - PQ 15978-26
Deputy Flynn asked about assessment of the impact on waiting lists, theatre utilisation, or paediatric surgical capacity. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 15855-26
Deputy O'Flynn asked about the gender identity services provided to children and adolescents. Read the HSE response.
- Published date:
- :
Question from Deputy Mattie McGrath - PQ 16222-26
Deputy McGrath asked about proposals to provide additional respite for adults and children with disabilities in Tipperary. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 15977-26
Deputy O'Flynn asked about the decision to authorise elective procedures without medical indication. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 16039-26
Deputy O'Flynn asked about medical card refusal rates. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 15814-26
Deputy O'Flynn asked about the pharmacoeconomic evaluations of tirzepatide and semaglutide. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 15813-26
Deputy O'Flynn asked about the reimbursement of tirzepatide for weight management. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 15815-26
Deputy O'Flynn asked about the full health technology assessment of tirzepatide for type 2 diabetes. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 15812-26
Deputy O'Flynn asked about the health technology assessments conducted in respect of tirzepatide. Read the HSE response.
- Published date:
- :